Of note, EGFR bypass activation has been reported as an early event in the setting of FGFR inhibition in FGFR3-altered urothelial cancer and in FGFR2-driven cholangiocarcinoma, suggesting the potential of EGFR targeting in progressive FGFR-driven diseases (32, 33). This evidence concerns the gene EGFR and cholangiocarcinoma.